Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer

Table 2

Immune checkpoint inhibitors in advanced or recurrent endometrial cancer.

Study	Design	No. of patients	Treatment	Primary end point	Results
KEYNOTE-28 [74]	Phase 1b	24	Pembrolizumab 10 mg/kg q 2 wks	RR	13% (95% CI 2.8-33.6)
ECHO-202/KEYNOTE-037	Phase 1/2, open label	7	Epacadostat 200 mg & pembrolizumab 200 mg	RR	RR 29%
Makker et al. [79]	Phase 1b/2, open label	23	Lenvatinib 20 mg & pembrolizumab 200 mg	RR	RR 48%
Fleming et al. [80]	Phase 1a	15	Atezolizumab 1200 mg or 15 mg/kg	Safety	RR 13%; Median PFS 1.7 mths
					Median OS 9.6 mths

No.: number; RR: response rate; CI: confidence interval; PFS: progression-free survival; mths: months; OS: overall survival.